VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | Significant CLL trial updates to come at ASH 2020

John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, Barts Cancer Institute, London, UK shares what important chronic lymphocytic leukemia (CLL) trial updates will be coming up at ASH 2020. A number of studies focused on combined ibrutinib plus venetoclax therapy will share results, including the US-based Phase II CAPTIVATE study. He also looks forward to seeing the 5-year MURANO study updates of venetoclax-rituximab in relapsed/refractory CLL, and further data on BTK inhibitors, such as LOXO-305. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter